Compare EQBK & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQBK | CERT |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.2M | 1.2B |
| IPO Year | 2015 | 2020 |
| Metric | EQBK | CERT |
|---|---|---|
| Price | $51.27 | $8.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $51.33 | $11.67 |
| AVG Volume (30 Days) | 87.2K | ★ 3.9M |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ 2.06 | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $74.58 | $4.18 |
| Revenue Next Year | $5.11 | $5.39 |
| P/E Ratio | $24.94 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $38.60 | $4.45 |
| 52 Week High | $52.27 | $13.88 |
| Indicator | EQBK | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 60.13 |
| Support Level | $44.45 | $6.05 |
| Resistance Level | $51.83 | $8.39 |
| Average True Range (ATR) | 0.93 | 0.37 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 61.50 | 82.62 |
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.